Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $4.4 million.

  • Coherus Oncology's Other Non-Current Assets fell 3971.8% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 3971.8%. This contributed to the annual value of $72.2 million for FY2024, which is 64519.93% up from last year.
  • Coherus Oncology's Other Non-Current Assets amounted to $4.4 million in Q3 2025, which was down 3971.8% from $5.0 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Other Non-Current Assets high stood at $72.2 million for Q4 2024, and its period low was $4.4 million during Q3 2025.
  • Its 5-year average for Other Non-Current Assets is $11.8 million, with a median of $9.1 million in 2024.
  • As far as peak fluctuations go, Coherus Oncology's Other Non-Current Assets skyrocketed by 234181.82% in 2021, and later crashed by 3971.8% in 2025.
  • Over the past 5 years, Coherus Oncology's Other Non-Current Assets (Quarter) stood at $10.0 million in 2021, then fell by 13.54% to $8.7 million in 2022, then grew by 11.74% to $9.7 million in 2023, then skyrocketed by 645.2% to $72.2 million in 2024, then crashed by 93.84% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $5.0 million for Q2 2025, and $5.7 million during Q1 2025.